The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| WST | -9.76% | +6.8% | +1.32% | +46,817% |
| S&P | +16.9% | +95.99% | +14.39% | +5,211% |
West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.
The company crushed analyst profitability estimates, both for its trailing quarter and for its full-year guidance.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $804.30M | 7.7% |
| Gross Profit | $293.50M | 10.7% |
| Gross Margin | 36.49% | 1.0% |
| Market Cap | $18.86B | -13.4% |
| Market Cap / Employee | $1.78M | 0.0% |
| Employees | 10.6K | 0.0% |
| Net Income | $140.00M | 2.9% |
| EBITDA | $216.70M | 4.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $628.50M | 28.0% |
| Accounts Receivable | $652.50M | 15.2% |
| Inventory | 438 | 9.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $280.10M | -2.4% |
| Short Term Debt | $22.90M | 10.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 12.64% | -0.8% |
| Return On Invested Capital | 19.42% | 0.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $133.90M | 35.5% |
| Operating Free Cash Flow | $197.20M | 9.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 48.96 | 35.16 | 32.78 | 38.86 | -12.73% |
| Price to Book | 8.63 | 6.03 | 5.86 | 6.44 | -23.86% |
| Price to Sales | 8.30 | 5.64 | 5.36 | 6.31 | -17.59% |
| Price to Tangible Book Value | 9.03 | 6.31 | 6.12 | 6.72 | -24.29% |
| Price to Free Cash Flow TTM | 110.49 | 66.09 | 55.88 | 59.82 | -28.60% |
| Enterprise Value to EBITDA | 112.78 | 96.48 | 78.46 | 86.39 | -17.76% |
| Free Cash Flow Yield | 0.9% | 1.5% | 1.8% | 1.7% | 40.05% |
| Return on Equity | 17.7% | 17.4% | 17.7% | 16.9% | -4.69% |
| Total Debt | $305.30M | $307.40M | $308.20M | $303.00M | -1.59% |
WST earnings call for the period ending June 30, 2022.
WST earnings call for the period ending March 31, 2022.
WST earnings call for the period ending December 31, 2021.
WST earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
